Back to top
more

Perrigo (PRGO)

(Delayed Data from NYSE)

$26.93 USD

26.93
1,950,153

+0.12 (0.45%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $26.94 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

DexCom (DXCM) Stock Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Abhinab Dasgupta headshot

3 Healthcare Stocks to Buy Amid Market Volatility

by Abhinab Dasgupta

Patterson (PDCO), Perrigo (PRGO) and GSK are three healthcare stocks that can lend solidity to one's portfolio today and provide big returns in the foreseeable future.

Should Value Investors Buy Perrigo (PRGO) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Stryker (SYK) Stock Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

West Pharmaceutical (WST) Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

PacBio (PACB) Gets New Order for Revio System From Bioscientia

by Zacks Equity Research

PacBio (PACB) receives new order for its Revio system from Bioscientia that will boost the latter's services. Here's how Revio can help Bioscientia improve diagnosis and treatment for monogenic disorders.

Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Stock

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Dexcom (DXCM) to Launch New Product in 2024, Ups Long-Term View

by Zacks Equity Research

Dexcom (DXCM) announces encouraging developments in 2024, including faster coverage for its products by private payers and new product launch for diabetic patients not on insulin.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Are Investors Undervaluing Perrigo (PRGO) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

How Much Upside is Left in Perrigo (PRGO)? Wall Street Analysts Think 49.5%

by Zacks Equity Research

The mean of analysts' price targets for Perrigo (PRGO) points to a 49.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

3 Top Dividend Stocks to Maximize Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Revvity (RVTY) Launches Single Solution for Drug Development

by Zacks Equity Research

Revvity (RVTY) Signals Software suite integrates streamlining data, global monitoring and customizable workflows and covers the entire Make-Test-Decide lifecycle, which can be centrally managed.

Perrigo (PRGO) Down 7.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

3 Top Dividend Stocks to Maximize Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Penumbra (PEN) Launches New Technology for Blood Clot Removal

by Zacks Equity Research

Penumbra (PEN) launches Lightning Bolt 7, a new technology that can remove blood clots faster and more efficiently with modulated aspiration.

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Revvity (RVTY) Launches New System for Autoimmune Diagnostics

by Zacks Equity Research

Revvity's (RVTY) EUROIMMUN launches UNIQO 160, a new automated system for autoimmune disease diagnostics using indirect immunofluorescence test.

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Stryker's (SYK) Q Guidance Successful in First Surgery

by Zacks Equity Research

Stryker (SYK) successfully completes first surgical case using its Q Guidance system with Cranial Guidance software. An Early Product Surveillance is underway for the combined technology.

Down -16% in 4 Weeks, Here's Why You Should You Buy the Dip in Perrigo (PRGO)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Perrigo (PRGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Abbott (ABT) Reports Upbeat Cardiomems Sensor Study Result

by Zacks Equity Research

Abbott's (ABT) MONITOR-HF is the third randomized, controlled trial that will provide significant health benefits to indicated heart failure patients.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on strong segmental growth.